5 February 2021
NEW YORK and LONDON - February 5, 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr Thomas Adams, Ph.D. as an executive director. Dr Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company s pre-clinical and clinical drug development programs and associated intellectual property. Dr Thomas H Adams (age: 78) Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. The Board believes that Dr. Adams executive leadership and the extensive healthcare expertise he has developed makes Dr. Adams ideally qualified to serve as an additional director of the Company.
NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director.
Dr. Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company s pre-clinical and clinical drug development programs and associated intellectual property.
Dr. Thomas H. Adams (age: 78)
Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. The Board believes that Dr. Adams executive leadership and the extensive healthcare expertise he has developed makes Dr. Adams ideally qualified to serve as an additional director of the Company.